Navigation Links
Product improves peptide identification for proteomics research

Agilent Technologies Inc. (NYSE: A) today introduced a high-performance ion trap mass spectrometer (MS) that allows pharmaceutical and academic life-science researchers to identify 60 to 80 percent more peptides than preceding models in proteomics applications, such as protein identification and biomarker discovery, potentially leading to a better understanding of diseases like cancer and speeding drug development efforts. The Agilent 1100 Series LC/MSD Trap XCT Ultra offers significantly improved scan cycle times, enabling collection of mass spectra at rates up to three times faster than its predecessors.

"The combination of the new LC/MSD Trap XCT Ultra with Agilent's breakthrough HPLC-Chip/MS technology will set a new standard for protein identification and analytical performance," said Ken Imatani, product marketing manager for Agilent's ion trap mass spectrometers. "The high resolution, scan speed and sensitivity of the LC/MSD Trap XCT Ultra make it a powerful tool for a wide range of qualitative applications in which high performance and productivity are essential, particularly in proteomics research."

"The LC/MSD Trap XCT Ultra is the latest example of Agilent's integrated approach to facilitating proteomics research, enabling researchers to solve their most challenging scientific questions more easily and with greater confidence," said Taia Ergueta, general manager of Agilent's Proteomics and LC/MS business. "The LC/MSD Trap XCT Ultra improves performance for a wide range of demanding applications in metabolite characterization, natural products screening, product degradation studies and food and environmental analysis, which require excellent sensitivity and fast scanning capability."

The LC/MSD Trap XCT Ultra, which is based on an advanced multipole ion trap technology, has a full-scan MS/MS sensitivity specification of 250 femtograms for reserpine. The system also has two new data-dependent neutral-loss analysis modes that provide e nhanced data quality for analysis of phosphopeptides and glycopeptides.

The LC/MSD Trap XCT Ultra will be unveiled at the American Association for Cancer Research annual meeting, April 15-20 (Booths 181 and 183).

Availability

The Agilent 1100 Series LC/MSD Trap XCT Ultra ion trap mass spectrometer (G4533AA) includes mass spectrometer, electrospray ionization source, data system and LC/MSD Trap software (6.0). It is expected to ship in July 2005. Further information is available at www.agilent.com/chem/iontrap.
About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 28,000 employees serve customers in more than 110 countries. Agilent had net revenue of $7.2 billion in fiscal year 2004. Information about Agilent is available on the Web at www.agilent.com.


'"/>

Source:Agilent


Related biology news :

1. Products containing specific probes for detecting alternative splice forms protected
2. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
3. Production of key Alzheimers protein monitored for first time in humans
4. Stem cell treatment improves mobility after spinal cord injury
5. Combination therapy improves AIDS-related lymphoma outcome
6. One fish, two fish: New MIT sensor improves fish counts
7. Man-made heart tissue improves cardiac performance
8. Viagra improves high altitude exercise performance up to 45% for some
9. Quitting smoking improves lung function considerably
10. Melatonin improves mood in winter depression
11. Brain protein improves stroke symptoms in rats, even when injected after 3 days
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology: